AGTR2, One Possible Novel Key Gene for the Entry of 2019-nCoV into Human Cells

Qinghua Cui, Chunmei Cui, Chuanbo Huang, Wanlu Zhou, Xiangwen Ji, Fenghong Zhang, Liang Wang, Yuan ZhouPreprints.org 2020 · DOI

TL;DR

This paper proposes Angiotensin II Receptor Type 2 (AGTR2) as a potential novel key gene for SARS-CoV-2 entry into human cells, offering a new perspective beyond the established ACE2 receptor. Computational analysis suggests AGTR2 not only interacts with the virus's spike protein but also exhibits higher binding affinity than ACE2, particularly in lung tissue.

What Problem Does This Paper Address?

The initial understanding of SARS-CoV-2 (the virus causing COVID-19) entry into human cells heavily relied on Angiotensin-Converting Enzyme 2 (ACE2) as the primary receptor. However, a puzzling observation was that while ACE2 is expressed in many organs, the lungs, the most severely affected organ, did not show the highest expression levels. This discrepancy led researchers to hypothesize that other genes might play crucial roles in facilitating viral entry, especially in the lungs. This paper aims to identify such potential co-receptors or alternative entry pathways.

Methods

The researchers employed a multi-pronged bioinformatics approach:

  • Protein-Protein Interaction (PPI) Network Analysis: They used STRING to build a functional association network centered on ACE2, identifying interacting proteins.
  • Gene Expression Analysis: They analyzed RNA-seq data from the Human Protein Atlas (HPA) and the Genotype-Tissue Expression (GTEx) database to assess the expression levels and tissue specificity of candidate genes, particularly focusing on receptors.
  • 3D Structure-Based Protein-Protein Docking: To predict the binding affinity between viral proteins and human receptors, they utilized docking servers like PRISM and ZDOCK. This involved obtaining experimental structures of AGTR2 and ACE2 from the Protein Data Bank (PDB) and predicting the structure of the SARS-CoV-2 spike protein.
  • Drug/Compound Screening: They screened the Connectivity Map (CMap) and JeaMoon Map (JMap) databases to identify compounds, biologics, and traditional Chinese medicines that could potentially down-regulate the expression of identified key genes.

Datasets

  • Human Protein Atlas (HPA) RNA-seq normal tissues: Used for gene expression profiling.
  • Genotype-Tissue Expression (GTEx) database: Also used for gene expression profiling across various human tissues.
  • Protein Data Bank (PDB): Provided experimental 3D structures for AGTR2 (entry 5UNG) and ACE2 (entry 1R42).
  • NCBI: Provided the sequence ID for the SARS-CoV-2 spike protein (QHR63290).
  • Connectivity Map (CMap) and JeaMoon Map (JMap): Used for screening potential agents that could modulate gene expression.

Key Insights and Ideas

  • AGTR2 as a potential co-receptor: The study highlights AGTR2 (Angiotensin II Receptor Type 2) as a strong candidate for a novel key gene in SARS-CoV-2 entry. This is significant because it moves beyond the singular focus on ACE2.
  • Higher binding affinity of AGTR2 to Spike protein: The computational docking results are particularly striking. AGTR2 showed a significantly higher binding affinity to the SARS-CoV-2 spike protein (-15.7 kcal/mol) compared to ACE2 (-6.9 kcal/mol). This suggests AGTR2 might be a more potent interaction partner.
  • Lung-specific expression of AGTR2: AGTR2 exhibits high expression and specificity in lung tissue, aligning with the observed primary target organ of SARS-CoV-2. This addresses the earlier puzzle regarding ACE2's expression pattern.
  • Potential therapeutic targets identified: The screening of CMap and JMap databases yielded a list of compounds and agents that could potentially decrease the expression of AGTR2, offering avenues for future therapeutic development.

Key Results

  • AGTR2 interacts with ACE2: The study found that AGTR2 interacts with ACE2.
  • AGTR2 has high expression and specificity in the lung: Gene expression analysis confirmed AGTR2's prominent presence in lung tissue.
  • AGTR2 shows stronger binding to SARS-CoV-2 Spike protein: Molecular docking simulations predicted a binding energy score of -15.7 kcal/mol for the AGTR2-Spike protein complex, versus -6.9 kcal/mol for the ACE2-Spike protein complex. For comparison, the SARS-CoV spike protein's interaction with ACE2 was -8.8 kcal/mol.
  • Identification of potential agents: Several agents, including Sambucus, Urtica, Andrographis, and valproic acid, were identified as potentially down-regulating AGTR2 expression.

Limitations and Future Work

  • Need for experimental validation: The authors explicitly state that their findings are based on computational predictions and require confirmation through biological experiments. This is the most critical limitation.
  • Other potential genes: While AGTR2 is highlighted, the paper also mentions PIGR and ADGRF1 as other receptor genes showing high and specific expression in lung tissue, suggesting they might also play a role. Future work could explore these further.
  • Mechanism of interaction: The precise mechanism by which AGTR2 facilitates viral entry, and its interplay with ACE2, needs further elucidation.
  • Therapeutic efficacy of identified agents: The identified agents require rigorous testing to determine their actual efficacy in reducing viral entry or disease severity.

Summary updated

Abstract

Recently, it was confirmed that ACE2 is the receptor of 2019-nCoV, the pathogen causing the recent outbreak of severe pneumonia in China. It is confused that ACE2 is widely expressed across a variety of organs and is expressed moderately but not highly in lung, which, however, is the major infected organ. It remains unclear why it is the lung but not other tissues among which ACE2 highly expressed is mainly infected. We hypothesized that there could be some other genes playing key roles in the entry of 2019-nCoV into human cells. Here we found that AGTR2 (angiotensin II receptor type 2), a G-protein coupled receptor, has interaction with ACE2 and is highly expressed in lung with a high tissue specificity. More importantly, simulation of 3D structure based protein-protein interaction reveals that AGTR2 shows a higher binding affinity with the Spike protein of 2019-nCov than ACE2 (energy score: -15.7 vs. -6.9 [kcal/mol]). Given these observations, we suggest that AGTR2 could be a putative novel gene for the the entry of 2019-nCoV into human cells but need further confirmation by biological experiments. Finally, a number of compounds, biologics and traditional Chinese medicine that could decrease the expression level of AGTR2 were predicted.
BibTeX
@misc{cui2020agtr,
  author = {Qinghua Cui and Chunmei Cui and Chuanbo Huang and Wanlu Zhou and Xiangwen Ji and Fenghong Zhang and Liang Wang and Yuan Zhou},
  title = {{AGTR2, One Possible Novel Key Gene for the Entry of 2019-nCoV into Human Cells}},
  year = {2020},
  doi = {10.20944/preprints202002.0194.v1},
  howpublished = {Preprints.org},
}
Figure